Critical Comparison: ANI Pharmaceuticals (ANIP) and Histogenics (HSGX)

ANI Pharmaceuticals (NASDAQ:ANIP) and Histogenics (NASDAQ:HSGX) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, dividends, profitability, valuation, risk and analyst recommendations.

Profitability

This table compares ANI Pharmaceuticals and Histogenics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
ANI Pharmaceuticals 7.69% 28.84% 12.71%
Histogenics N/A N/A -60.55%

Analyst Ratings

This is a summary of recent ratings and price targets for ANI Pharmaceuticals and Histogenics, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ANI Pharmaceuticals 0 0 3 0 3.00
Histogenics 0 2 2 0 2.50

ANI Pharmaceuticals currently has a consensus target price of $72.33, indicating a potential upside of 9.65%. Histogenics has a consensus target price of $3.17, indicating a potential upside of 2,521.41%. Given Histogenics’ higher probable upside, analysts clearly believe Histogenics is more favorable than ANI Pharmaceuticals.

Institutional and Insider Ownership

59.8% of ANI Pharmaceuticals shares are held by institutional investors. Comparatively, 15.7% of Histogenics shares are held by institutional investors. 33.1% of ANI Pharmaceuticals shares are held by insiders. Comparatively, 19.7% of Histogenics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Earnings and Valuation

This table compares ANI Pharmaceuticals and Histogenics’ top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
ANI Pharmaceuticals $201.58 million 3.88 $15.49 million $4.61 14.31
Histogenics N/A N/A -$26.41 million ($0.98) -0.12

ANI Pharmaceuticals has higher revenue and earnings than Histogenics. Histogenics is trading at a lower price-to-earnings ratio than ANI Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

ANI Pharmaceuticals has a beta of 2.41, meaning that its share price is 141% more volatile than the S&P 500. Comparatively, Histogenics has a beta of 3.52, meaning that its share price is 252% more volatile than the S&P 500.

Summary

ANI Pharmaceuticals beats Histogenics on 11 of the 13 factors compared between the two stocks.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States. It focuses on producing controlled substances, anti-cancer (oncolytics), hormones and steroids, and complex formulations. The company offers Erythromycin Ethylsuccinate to treat infections; Esterified Estrogen with Methyltestosterone for treating vasomotor symptoms of menopause; Etodolac to treat pain caused by osteoarthritis, rheumatoid arthritis, and other conditions; Fenofibrate for treating hypercholesterolemia; Flecainide to treat arrhythmia; Fluvoxamine for treating obsessive-compulsive and social anxiety disorders; and hydrocortisone enema and cortenema to treat ulcerative colitis. It also provides Hydrocortisone Rectal Cream to treat inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses; Lithium Carbonate ER and Lithobid for bipolar disorder; Mesalamine Enema to treat distal ulcerative colitis, proctosigmoiditis, or proctitis; Methazolamide to treat ocular conditions; and Metoclopramide and Reglan to treat gastroesophageal reflux. In addition, the company offers Nilutamide to treat metastatic prostate cancer; Nimodipine that reduces the ischemic deficits in patients with subarachnoid hemorrhage; Opium Tincture to treat diarrhea; Oxycodone capsules and oral solution for severe and chronic pain; Propafenone to treat arrhythmia; Propranolol ER, Inderal LA, and Pindolol for managing hypertension in patients with angina pectoris; and Vancomycin and Vancocin for use in treating C. difficile-associated diarrhea and enterocolitis. Further, it provides contract manufacturing services for other pharmaceutical companies. The company markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, and group purchasing organizations. ANI Pharmaceuticals, Inc. is headquartered in Baudette, Minnesota.

Histogenics Company Profile

Histogenics Corporation, a clinical-stage company, focuses on the development of restorative cell therapies in the United States. The company offers NeoCart, a tissue implant, which is in Phase III clinical trial to treat tissue injury in the field of orthopedics, specifically cartilage damage in the knee. It has an exclusive channel collaboration agreement with Intrexon Corporation for the development and commercialization of allogeneic genetically modified chondrocyte cell therapeutics for the treatment or repair of damaged articular hyaline cartilage in humans. Histogenics Corporation was founded in 2000 and is headquartered in Waltham, Massachusetts.

Receive News & Ratings for ANI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.